Biopharmaceutics & Drug disPosition

Papers
(The TQCC of Biopharmaceutics & Drug disPosition is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Can a monthly exenatide extended release regimen provide a therapeutic and cost benefit?17
13
Irinotecan‐induced gastrointestinal damage alters the expression of peptide transporter 1 and absorption of cephalexin in rats13
12
In situ evaluation of the impact of metformin or verapamil coadministration with vildagliptin on its regional absorption from the rabbit’s intestine11
11
Issue Information11
Febuxostat and its major acyl glucuronide metabolite are potent inhibitors of organic anion transporter 3: Implications for drug‐drug interactions with rivaroxaban11
10
Comparison of biomarker and chromatographic analytical approaches to pharmacokinetic study of sitagliptin9
9
Metabolism of testosterone and progesterone by cytochrome P450 2C19 allelic variants8
8
Decreased plasma exposure of clopidogrel active metabolite in rats after long‐term treatment with clopidogrel7
Norvancomycin plasma concentration monitoring in hemodialysis patients with end stage kidney disease: A retrospective cohort study7
Issue Information7
Issue Information7
In Vivo Animal Spices and Experimental Technique to Evaluate Sustained Release Granules6
6
Changes in uridine 5′‐diphospho‐glucuronosyltransferase 1A6 expression by histone deacetylase inhibitor valproic acid6
Heterogeneous brain distribution of bumetanide following systemic administration in rats6
6
6
Icaritin exhibits potential drug–drug interactions through the inhibition of human UDP‐glucuronosyltransferase in vitro6
In vitro and ex vivo experimental models for evaluation of intranasal systemic drug delivery as well as direct nose‐to‐brain drug delivery5
5
Fluorouracil uptake in triple‐negative breast cancer cells: Negligible contribution of equilibrative nucleoside transporters 1 and 25
Physiologically based pharmacokinetic modelling of acetaminophen in preterm neonates—The impact of metabolising enzyme ontogeny and reduced cardiac output5
Evaluation on absorption risks of amentoflavone after oral administration in rats5
Influence of Gegenqinlian decoction on pharmacokinetics and pharmacodynamics of saxagliptin in type 2 diabetes mellitus rats5
5
Across‐species meta‐analysis of dexamethasone pharmacokinetics utilizing allometric and scaling modeling approaches5
Comparison of tissue pharmacokinetics of esflurbiprofen plaster with flurbiprofen tablets in patients with knee osteoarthritis: A multicenter randomized controlled trial4
Investigating CNS distribution of PF‐05212377, a P‐glycoprotein substrate, by translation of 5‐HT6 receptor occupancy from non‐human primates to humans4
Pharmacokinetic control of orally dosed cyclosporine A with mucosal drug delivery system4
Metabolism, pharmacokinetics, and anticonvulsant activity of a deuterated analog of the α2/3‐selective GABAkine KRM‐II‐814
In vitro evaluation of 99mTc‐sultamicillin for infection imaging4
Regional distributions of curcumin and tetrahydrocurcumin in the liver and small intestine of rats when orally co‐administered with quercetin and paeoniflorin4
Aging and brain free cholesterol concentration on amyloid‐β peptide accumulation in guinea pigs4
4
0.050727128982544